Platinum-Resistant Primary Peritoneal Carcinoma

Platinum-Resistant Primary Peritoneal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 16
Recruiting: 5
Ph III recruiting: 1
Growth YoY: —
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04616534	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	active not recruiting	Phase 1	14	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT02650986	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1	active not recruiting	Phase 1 / Phase 2	15	Roswell Park Cancer InstituteOTHER	1